Telomere Parameters in Patients With Nonalcoholic Fatty Liver (telomereFL)
|ClinicalTrials.gov Identifier: NCT01694342|
Recruitment Status : Unknown
Verified July 2012 by Meir Medical Center.
Recruitment status was: Not yet recruiting
First Posted : September 27, 2012
Last Update Posted : September 27, 2012
Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.
Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group  and others . Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.
Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability . It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.
|Condition or disease|
|FATTY LIVER NO MALIGNANCY NO DECOMPENSATED ILLNESS|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver|
|Study Start Date :||September 2012|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01694342
|Contact: Yona Kitay-Cohen, MDfirstname.lastname@example.org|
|Meir Hospital||Not yet recruiting|
|Kefar Saba, Israel|
|Contact: Yona Kitay-Cohen, MD +97297471560 email@example.com|
|Principal Investigator: Yona Kitay-Cohen, MD|